---
title: "Insider Move at Charles River Labs: Director Cashes In on Company Stock"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296571643.md"
description: "Charles River Labs director Nancy C. Andrews sold 573 shares worth $163,442 on August 20, 2026. This insider move coincides with positive market reactions to the company's Q2 earnings beat, margin expansion, and raised guidance. Despite analyst upgrades driven by recovering demand and strong DSA bookings, TipRanks' AI Analyst Spark rates CRL as Neutral due to recent financial losses and negative P/E, though technical signals remain bullish."
datetime: "2026-08-21T02:12:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296571643.md)
  - [en](https://longbridge.com/en/news/296571643.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296571643.md)
generator: "portal-rs"
---

# Insider Move at Charles River Labs: Director Cashes In on Company Stock

New insider activity at Charles River Labs ( (CRL) ) has taken place on August 20, 2026.

Director Nancy C. Andrews has recently reduced her stake in Charles River Laboratories, selling 573 shares of the company’s stock. The transaction, valued at $163,442, highlights a notable insider move that may draw attention from investors tracking executive and director trading activity.

Charles River Labs shares moved higher over the last day as investors reacted to a Q2 beat, margin expansion and a guidance raise that signaled a return to modest organic growth. Management’s emphasis on robust DSA bookings, a rising backlog, improved free cash flow outlook and strong manufacturing margins helped offset concerns over RMS softness, higher corporate costs and tax headwinds.

Analysts raised price targets largely on evidence that discovery and safety assessment demand is sustainably recovering, supported by healthy biotech funding and stable pharma activity. The upgraded outlook for 2026 EPS and revenue, plus visibility from a 1.19 DSA book‑to‑bill and strategic initiatives like AI‑enabled partnerships and portfolio optimization, reinforced confidence in more durable top‑ and bottom‑line growth despite ongoing segment and funding pressures.

**Spark’s Take on CRL Stock**

According to Spark, TipRanks’ AI Analyst, CRL is a Neutral.

The score is held back primarily by weakened financial performance (losses and steep TTM revenue decline) and limited valuation support due to negative earnings (negative P/E). Offsetting factors include strong technical momentum (price well above key moving averages with positive MACD) and a constructive earnings-call setup with raised FY2026 guidance and expected margin expansion, though execution and timing risks (RMS softness, back-loaded benefits, and higher corporate costs/tax headwind) remain.

To see Spark’s full report on CRL stock,  
 click here. 

**More about Charles River Labs**

**YTD Price Performance:** 45.38%

**Average Trading Volume:** 896,432

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $13.33B

### Related Stocks

- [CRL.US](https://longbridge.com/en/quote/CRL.US.md)

## Related News & Research

- [Charles River Labs director Nancy C. Andrews disposes of 573 common shares worth $163,442.52](https://longbridge.com/en/news/296533503.md)
- [Charles River and MVC to develop enterovirus vaccine](https://longbridge.com/en/news/296594849.md)
- [Charles River partners with Medigen Vaccine Biologics on NGS-backed multivalent enterovirus vaccine development](https://longbridge.com/en/news/296486690.md)
- [Famous Hedge Fund Tiger Global Opened a New Position in This 1 AI Stock](https://longbridge.com/en/news/296381679.md)
- [A mysterious free AI model is impressing developers. And nobody knows who made it.](https://longbridge.com/en/news/296687985.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**